This is the Genome Era. To solve life’s most complex problems, the dreams of our greatest minds must come together with world-changing tools. From groundbreaking sequencing platforms like the new NovaSeq X series to world-class microarray systems and informatic solutions, Illumina offers the tools that fit the complex needs of researchers across the genomic spectrum. Ranging from single-cell and whole-genome sequencing to population-scale genomics, come learn how Illumina can partner with you in advancing the future of genomics. Visit Illumina booth 1111 at ASHG 2022, and attend our Industry Education session, CoLabs, and Booth Talks to learn more about our products, partnerships, and solutions.
End-to-end informatics solutions enabling precision medicine
Tuesday, October 25 at 9 AM (PT)
JW Marriott LA Live Ballroom E–J
Hybrid (online and in-person)
Refreshments and light lunch will be provided.
This special half-day ancillary event includes presentations and panel discussions from industry leaders implementing their own Precision Medicine programs connecting data across the entire genomics workflow from sample management through interpretation.
Improving human health through Illumina microarray solutions
Tuesday, October 25 at 6:30 PM (PT)
JW Marriott LA Live Ballroom E–J
Microarrays continue to play a key role in providing a variety of different data types that are relevant in clinical research and can be applied at scale due to their low-cost relative to other options. Array data continues to be combined with other -omics data to drive further insights into human biology, particularly in the context of translational research and the utility of this information in healthcare.
Illumina innovation roadmap featuring the NovaSeq X series
Wednesday, October 26 at 12:30 PM (PT)
Room 304 – LA Convention Center
Lunch will be served.
Over the last several years, many health challenges were magnified due to the pandemic, driving historic innovation across the global scientific community. In particular, the crucial role that genomics can play in transforming precision medicine and care delivery came to the forefront. From vaccines and therapies to early cancer detection and diagnostics, there was greater adoption of genomic medicine in the last year than ever before in history – and this is just the beginning. Technologic advancements in sequencing by synthesis (SBS) chemistry and bioinformatics, together with long-read sequencing assays that can deliver contiguous data up to 10Kb, expand the breadth of applications on Illumina platforms by enabling the most accurate and comprehensive view of the genome, including SNPs, indels and structural variants that will fuel the next era of genomic medicine. In this presentation, we will describe the technical innovations that are driving improvements in next-generation sequencing capabilities and highlight how this technology enables precision medicine applications.
Ashley Van Zeeland, PhD, MBA
VP, Head of Illumina Open Innovation
Joel Fellis, PhD
VP Product Management, Sequencing Platforms
SVP and General Manager, Americas
Illumina Complete Long-Read technology: Detailed insights into complex genomes
Thursday, October 27 at 10 AM (PT)
CoLab Theater 1 – LA Convention Center
Illumina next-generation sequencing (NGS) has been the most widely adopted technology for human whole-genome sequencing (WGS), delivering an accurate, scalable, cost-effective solution, featured in over 300,000 scientific publications. However, a small portion of the genome remains challenging to map due to highly repetitive or highly homologous regions. Illumina Complete Long-Read technology, previously announced as Infinity, will address these edge cases and accelerate access to the remaining ~5% of genic regions. In this presentation, we will describe the benefits of Illumina’s novel long-read technology, including accuracy, scalability, and workflow improvements. In addition, we will discuss how the Complete Long-Read technology is complemented by other technical innovations in our roadmap.
Manager, Product Management
Our specialist will be delivering in-booth conversations on sequencing systems, array solutions, library prep, software and much more!
|Wednesday, October 26|
|10:10–10:25 AM||NextSeq 1000/2000|
|Thursday, October 27|
|10:30–10:40 AM||NovaSeq X|
|1:45–2:00 PM||Library prep|
Broadening access to and participation in genetic testing and research: A discussion about barriers and potential solutions
Friday, October 28 at 1 PM (PT)
CoLab Theater 2 – LA Convention Center
A joint session with Illumina and Invitae
ASHG Impact Partners, Invitae and Illumina are pleased to present a special session focused on barriers to clinical genetic testing and genetics research participation along with a discussion about potential ways to overcome these barriers to broaden access and participation and expand the benefit of genetics and genomics to more people. Like ASHG, Impact Partners are committed to a more diverse, equitable, and inclusive future that ensures people everywhere benefit from advances in the field of human genetics and genomics.
Janina Jeff, PhD, MS
Staff Bioinformatics Scientist
Dianalee McKnight, PhD, FACMG
Medical Affairs Director